JPRN-UMIN000028874招募中未知
efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer - efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer
Fukushima Medical University School of Medicine0 个研究点目标入组 100 人开始时间: 2017年9月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 75years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •The patients for whom Dutasteride or another androgen deprivation therapy was administrated.
研究者
相似试验
招募中
不适用
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.Metastatic Prostate CancerACTRN12617001116314St Vincent's Hospital, Sydney20
进行中（未招募）
1 期
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic prostate cancerEUCTR2018-004853-26-FITurku University Hospital35
进行中（未招募）
1 期
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)Prostate cancerEUCTR2017-002345-29-FITurku University Hospital5
招募中
3 期
Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence after surgeryProstate Cancer2024-517666-41-00Instituto De Investigacion En Oncología Radioterapica FEOR534
进行中（未招募）
不适用
Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer.Metastatic castration sensitive prostate cancerEUCTR2014-000273-39-GBBelfast Health and Social Care Trust